3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Turcot syndrome
1
Rhabdoid Tumor
1
Pathologic Complete Response
1
Neuroectodermal Tumors, Primitive
1
Nasopharyngeal Carcinoma
1
Medulloblastoma
1
Lung Neoplasms
1
Esophagitis
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Choroid Plexus Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Burkitt Lymphoma
1
Brain Neoplasms
1
Anus Neoplasms
1
Interventions
Carboplatin
6
pembrolizumab
3
Paclitaxel
3
Observation
3
Capecitabine
3
Azacitidine
3
venetoclax
2
pertuzumab
2
olaparib
2
durvalumab
2
Tretinoin
2
Trastuzumab
2
Standard of Care
2
Oxaliplatin
2
Irinotecan
2
Immunotherapy
2
Chemoradiotherapy
2
130-nm albumin-bound paclitaxel
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
toripalimab
1
tislelizumab
1
tegafur-gimeracil-oteracil
1
taxane
1
talazoparib
1
tagraxofusp
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
Induction Chemotherapy
×
1 year
×
Clear all
NCT07472868
2026-03-16
MEND-IT II
Catharina Ziekenhuis Eindhoven
Phase 3
Not yet recruiting
394 enrolled